Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

NCT00774397 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

719

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: BI 201335 NA 240 mg QD / LI
DRUG: PegIFN/RBV
DRUG: BI 201335 NA 120mg QD / LI
DRUG: PegIFN/RBV
DRUG: BI 201335 NA 240 mg QD
DRUG: PegIFN/RBV
DRUG: BI 201335 NA 240 mg QD
DRUG: PegIFN/RBV
DRUG: BI 201335 NA 240 mg BID
DRUG: PegIFN/RBV
DRUG: PegIFN/RBV
DRUG: BI 201335 NA 240 mg QD
DRUG: PegIFN/RBV
DRUG: Placebo

Sponsor

Boehringer Ingelheim